[New therapeutic approaches in stroke prevention].
Stroke is the second most common cause of death and dementia and the number one cause of serious disability in adults in developed countries. After the stroke there remains a maximum vascular risk of recurrence (stroke, heart attack or vascular death). The known vascular risk factors (RF) could only explain 50% of vascular events. A better knowledge of atherogenesis, of the mechanisms that cause instability in the atheroma plaque and of new vascular RF gives rise to new preventive therapeutic approaches. This knowledge is the result of new clinical trials, such as the use of ACE inhibitors, statins, vitamins related with homocysteine, and the use of antihypertensive drugs to prevent cognitive deterioration or dementia, which add to those that have already been conducted.
Gil-Nuñez
A C
AC
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015140:Dementia, Vascular / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy* / Q000517:prevention & control*; D014815:Vitamins / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014815:Vitamins